Cyclooxygenase-2 (COX-2) As a Predictive Marker for the Use of COX-2 Inhibitors in Advanced Non-Small-Cell Lung Cancer

被引：18
作者：
Edelman, Martin J. [1 ]
Hodgson, Lydia [2 ]
Wang, Xiaofei [2 ]
Kratzke, Robert A. [3 ]
Vokes, Everett E. [4 ]
机构：
[1] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[2] Duke Univ, Durham, NC USA
[3] Univ Minnesota, Minneapolis, MN USA
[4] Univ Chicago, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 16期
关键词：
CELECOXIB; EXPRESSION; CHEMOTHERAPY; BIOMARKER; ERLOTINIB;
D O I：
10.1200/JCO.2011.41.4581
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2019 / 2020
页数：2
相关论文
共 9 条
[1]   Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer [J].
Altorki, NK ;
Port, JL ;
Zhang, F ;
Golijanin, D ;
Thaler, HT ;
Duffield-Lillico, AJ ;
Subbaramaiah, K ;
Dannenberg, AJ .
CLINICAL CANCER RESEARCH, 2005, 11 (11) :4191-4197
[2]   Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib plus chemotherapy - Cancer and leukemia group B trial 30203 [J].
Edelman, Martin J. ;
Watson, Dee ;
Wang, Xiaofei ;
Morrison, Carl ;
Kratzke, Robert A. ;
Jewell, Scott ;
Hodgson, Lydia ;
Mauer, Ann M. ;
Gajra, Ajeet ;
Masters, Gregory A. ;
Bedor, Michelle ;
Vokes, Everett E. ;
Green, Mark J. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) :848-855
[3]   Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation [J].
Fabi, Alessandra ;
Metro, Giulio ;
Papaldo, Paola ;
Mottolese, Marcella ;
Melucci, Elisa ;
Carlini, Paolo ;
Sperduti, Isabella ;
Russillo, Michelangelo ;
Gelibter, Alain ;
Ferretti, Gianluigi ;
Tomao, Silverio ;
Milella, Michele ;
Cognetti, Francesco .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (04) :717-725
[4]   The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib [J].
Fidler, Mary J. ;
Agrgiris, Athanassios ;
Patel, Jyoti D. ;
Johnson, David H. ;
Sandler, Alan ;
Villaflor, Victoria M. ;
Coon, John ;
Buckingham, Lela ;
Kaiser, Kelly ;
Basu, Sanjib ;
Bonomi, Philip .
CLINICAL CANCER RESEARCH, 2008, 14 (07) :2088-2094
[5]  
Gitlitz BJ, 2011, J CLIN ONCOL S15, V29, p482s
[6]   Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients With Advanced Non-Small-Cell Lung Cancer: The NVALT-4 Study [J].
Groen, Harry J. M. ;
Sietsma, Hannie ;
Vincent, Andrew ;
Hochstenbag, Monique M. H. ;
van Putten, John W. G. ;
van den Berg, Anke ;
Dalesio, Otilia ;
Biesma, Bonne ;
Smit, Hans J. M. ;
Termeer, Arien ;
Hiltermann, T. Jeroen N. ;
van den Borne, Ben E. E. M. ;
Schramel, Franz M. N. H. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) :4320-4326
[7]   A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer [J].
Reckamp, Karen L. ;
Krysan, Kostyantyn ;
Morrow, Jason D. ;
Milne, Ginger L. ;
Newman, Robert A. ;
Tucker, Christopher ;
Elashoff, Robert M. ;
Dubinett, Steven M. ;
Figlin, Robert A. .
CLINICAL CANCER RESEARCH, 2006, 12 (11) :3381-3388
[8]   Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma [J].
Rini, BI ;
Weinberg, V ;
Dunlap, S ;
Elchinoff, A ;
Yu, N ;
Bok, R ;
Simko, J ;
Small, EJ .
CANCER, 2006, 106 (03) :566-575
[9]   Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2 - Evidence for involvement of ERK1/2 and p38 mitogen-activated protein kinase pathways [J].
Subbaramaiah, K ;
Hart, JC ;
Norton, L ;
Dannenberg, AJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (20) :14838-14845
1